[1]王晓莉,张维文,张方圆,等.氯吡格雷抵抗对椎动脉狭窄支架术后再狭窄的影响[J].中国临床神经外科杂志,2022,27(07):585-586.[doi:10.13798/j.issn.1009-153X.2022.07.019]
点击复制

氯吡格雷抵抗对椎动脉狭窄支架术后再狭窄的影响()
分享到:

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
27
期数:
2022年07期
页码:
585-586
栏目:
经验介绍
出版日期:
2022-07-31

文章信息/Info

文章编号:
1009-153X(2022)07-0585-02
作者:
王晓莉张维文张方圆魏琰
053000 河北,衡水市人民医院神经医学中心(王晓莉、张维文、张方圆、魏琰)
关键词:
椎动脉狭窄支架植入术氯吡格雷抵抗术后再狭窄
分类号:
R743;R815.2
DOI:
10.13798/j.issn.1009-153X.2022.07.019
文献标志码:
B
摘要:
目的 探索氯吡格雷抵抗对椎动脉狭窄支架术后再狭窄的影响。方法 回顾性分析2014年1月至2020年12月支架置入术治疗的167例椎动脉V1段狭窄的临床资料。术后3 d血栓弹力图检测MA-ADP≥47 mm为氯吡格雷抵抗。术后支架内再狭窄定义术后1年CTA示椎动脉再狭窄率≥50%。结果 167例中,氯吡格雷抵抗75例。术后1周内无症状性卒中及死亡病例。术后随访1年,椎动脉发生再狭窄51例(30.5%)。多因素Cox回归分析显示氯吡格雷抵抗(HR=2.18;95% CI 1.23~3.88;P=0.015)是支架术后再狭窄的独立危险因素。结论 椎动脉狭窄支架术后存在氯吡格雷抵抗的病人,支架内再狭窄风险增高。

参考文献/References:

[1]Caplan LR, Wityk RJ, Glass TA, et al. New England medicalcenter posterior circulation registry [J]. Ann Neurol, 2004,56(3): 389-398.
[2]Markus HS, Larsson SC, Kuker W, et al. Stenting for symptomatic vertebral artery stenosis: The Vertebral Artery Ischaemia Stenting Trial [J]. Neurology, 2017, 89(12): 1229-1236.
[3]Li J, Hua Y, Needleman L, et al. Arterial occlusions increase the risk of in-stent restenosis after vertebral artery ostium stenting [J]. J Neurointerv Surg, 2019, 11(6): 574-578.
[4]Li L, Wang X, Yang B, et al. Validation and comparison of drug eluting stent to bare metal stent for restenosis rates following vertebral artery ostium stenting: a single-center real-world study [J]. Interv Neuroradiol, 2020, 26(5): 629-636.
[5]Fiolaki A, Katsanos AH, Kyritsis AP, et al. High on treatment platelet reactivity to aspirin and clopidogrel in ischemic stroke: a systematic review and meta-analysis [J].
J Neurol Sci, 2017, 376: 112-116.
[6]Wang YL, Chen WQ, Lin Y, et al. Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack:
open label, blinded endpoint, randomised controlled phase II trial [J]. BMJ, 2019, 365: l2211.
[7]Zhu HC, Li Y, Guan SY, et al. Efficacy and safety of individually tailored antiplatelet therapy in patients with acute coronary syndrome after coronary stenting: a single center, randomized, feasibility study [J]. J Geriatr Cardiol, 2015, 12(1): 23-29.
[8]Yang H, Li Y, Jiang Y. Insufficient platelet inhibition and thromboembolic complications in patients with intracranial aneurysms after stent placement [J]. J Neurosurg, 2016, 12(2): 247-253.
[9]Li W, Zhu W, Wang A, et al. Effect of adjusted antiplatelet therapy on preventing ischemic events after stenting for intracranial aneurysms [J]. Stroke, 2021, 52(12): 3815-
3825.
[10]Matula C, Trattnig S, Tschabitscher M, et al. The course of the prevertebral segment of the vertebral artery: anatomy and clinical significance [J]. Surg Neurol, 1997, 48(2): 125-131.
[11]Albuquerque FC, Fiorella D, Han P, et al. A reappraisal of angioplasty and stenting for the treatment of vertebral origin stenosis [J]. Neurosurgery, 2003, 53(3): 607-614.

相似文献/References:

[1]魏 恒 马江红 张 华 曹 敏 徐丽琴 曾静霞.Wingspan支架置入术治疗椎动脉狭窄的疗效观察[J].中国临床神经外科杂志,2015,(07):430.[doi:10.13798/j.issn.1009-153X.2015.07.017]
[2]燕景锋 樊立华 任崇文 贾增强 何金超 孙 鹏.单一支架置入术治疗椎-锁骨下动脉联合狭窄[J].中国临床神经外科杂志,2017,(05):290.[doi:10.13798/j.issn.1009-153X.2017.05.002]
 YAN Jing-feng,FAN Li-hua,REN Chong-wen,et al.Outcomes of single stent technique in subclavian-vertebral artery bifurcation series stenoses[J].,2017,(07):290.[doi:10.13798/j.issn.1009-153X.2017.05.002]
[3]刘佳明 潘鹏宇 陈立刚等.紫杉醇药物涂层球囊成形术治疗症状性椎动脉开口处狭窄的疗效[J].中国临床神经外科杂志,2021,26(02):65.[doi:10.13798/j.issn.1009-153X.2021.02.001]
 LIU Jia-ming,PAN Peng-yu,CHEN Li-gang,et al.Paclitaxel drug-coated balloon angioplasty for patients with symptomatic vertebral artery origin stenosis[J].,2021,26(07):65.[doi:10.13798/j.issn.1009-153X.2021.02.001]

备注/Memo

备注/Memo:
(2022-04-27收稿,2022-05-28修回)
更新日期/Last Update: 2022-08-31